Results 21 to 30 of about 8,155 (200)
The treatment of Graves' disease in children and adolescents [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2014 Graves' disease (GD) accounts for 10%-15% of thyroid disorders in children and adolescents. The use of antithyroid drugs as the initial treatment option in GD is well accepted.
Hae Sang Lee, Jin Soon Hwang
doaj +1 more source
Frontiers in Pharmacology, 2020 Background: Drugs can alter the gut microbiota structure, and gut microbiota dysbiosis in turn is correlated with drug side effects through the intestinal endotoxemia hypothesis.
Jiayu Sun +8 more
doaj +1 more source
Prevalence, Treatment Status, and Comorbidities of Hyperthyroidism in Korea from 2003 to 2018: A Nationwide Population Study [PDF]
Endocrinology and Metabolism, 2023 Background This study aimed to investigate the changes of incidence and treatment of choice for hyperthyroidism from 2003 to 2018 and explore the treatment-related complications and concomitant comorbidities in South Korea using data from the National ...
Hwa Young Ahn +6 more
doaj +1 more source
Selenium analogues of antithyroid drugs - recent developments [PDF]
, 2008 Thyroxine (T4), the main secretory hormone of the thyroid gland, is produced on thyroglobulin by thyroid peroxidase (TPO)/H2O2/iodide system and deiodinated to its active form (T3) by a selenocysteine-containing enzyme, iodothyronine deiodinase (ID). The
Mugesh, Govindasamy, Roy, Gouriprasanna
core +3 more sources
Frontiers in Endocrinology, 2023 IntroductionRadioactive iodine (RAI) therapy is a critical component in the post-surgical management of thyroid cancer patients, as well as being a central therapeutic option in the treatment of hyperthyroidism.
Riazul Zannat +10 more
doaj +1 more source
Effect of Addition of Thyroxine in the Treatment of Graves’ Disease: A Systematic Review
Frontiers in Endocrinology, 2021 Graves’ disease is the most common cause of hyperthyroidism. Antithyroid drugs, radioiodine ablation, and surgery are the main treatments. Research has demonstrated that adding thyroxine to antithyroid therapy can improve the remission rate, and many ...
Jun Li +6 more
doaj +1 more source
Risk Factors for the Relapse of Graves’ Disease Following Withdrawal of Antithyroid Drugs
Endocrinology Research and Practice, 2021 Objectives: The treatment of Graves’ disease (GD) with antithyroid drugs (ATD) is associated with a risk of relapse. The rate and predictive factors of GD are controversial.
Meriem YAZIDI +5 more
doaj +1 more source
Population-based studies of antithyroid drugs and sudden cardiac death [PDF]
, 2009 WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Thyroid hormone free T4 is associated with QTc-interval prolongation, which is a risk factor for sudden cardiac death.
Hofman, A. (Albert) +11 more
core +1 more source
Severe Neutropenia and Agranulocytosis Related to Antithyroid Drugs: A Study of 30 Cases Managed in A Single Reference Center. [PDF]
Medicines (Basel), 2020 Background: The most important series devoted to antithyroid drug-induced severe neutropenia and agranulocytosis are Japanese studies, almost specifically in relation to the intake of methimazole.
Andrès E +8 more
europepmc +2 more sources
A Case of Neonatal Thyrotoxicosis with Cardiac Insufficiency [PDF]
Neonatal Medicine, 2021 Neonatal thyrotoxicosis is rare and most of the cases are secondary to maternal Graves’ disease. It is usually transient, but can be associated with significant morbidity and mortality if not recognized promptly and treated adequately.
Ji Eun Jeong +4 more
doaj +1 more source